Post Market Clinical Follow Up Study to Collect Additional Data and Imaging

Exclusion Criteria

• •Is pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study.
• •The subject is hypersensitive to light in the near infrared wavelength region.
• •The subject takes medication which is known to increase sensitivity to sunlight.
• •The subject has seizure disorders triggered by light.
• •The subject takes or has taken oral isotretinoin, such as Accutane®, within the last six months.
• •The subject has an active localized or systemic infection, or an open wound in area being treated.
• •The subject has a significant systemic illness, such as lupus, or an illness localized in area being treated.
• •The subject has common acquired nevi that are predisposed to the development of malignant melanoma.
• •The subject has herpes simplex in the area being treated.
• •The subject is receiving or has received gold therapy.
• •The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months to entering this study.
• •The subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.